Asia Pacific (APAC) Flu Diagnostic and Treatment Market - Strategic Insights and Forecasts (2026-2031)

The Asia-Pacific (APAC) flu diagnostic and treatment market is projected to register a strong CAGR during the forecast period (2026-2031).

Key Highlights

Market Overview

Hospitals, laboratories, clinics, and public health agencies require tests that can distinguish influenza from other respiratory infections and support treatment decisions within clinically useful timeframes. WHO surveillance data also shows that influenza activity varies across the region, making continuous testing capacity important for both patient care and public health monitoring.

The commercial mix spans rapid antigen tests, molecular assays, multiplex respiratory panels, and antiviral medicines. Rapid tests remain relevant where low equipment requirements and short turnaround times matter, while molecular and multiplex systems command greater value where sensitivity, pathogen differentiation, and laboratory workflow are priorities. WHO guidance recognizes that rapid influenza diagnostic tests can be used in clinics and settings without laboratory services, while molecular tests provide more reliable detection at higher cost.

Buyer decisions increasingly reflect the need to distinguish influenza A and B from SARS-CoV-2, RSV, and other respiratory pathogens. This favors platforms that combine several targets without materially extending turnaround time. bioMérieux, Roche, QIAGEN, Seegene, and QuidelOrtho are expanding or maintaining portfolios around multiplex and near-patient respiratory testing, indicating that assay breadth, workflow simplicity, and speed are becoming important competitive factors.

Treatment demand remains closely linked to early diagnosis and clinical risk. CDC guidance states that influenza antivirals work best when started within one to two days after symptom onset, while people aged 65 years and older, young children, hospitalized patients, and those at higher risk of complications receive particular attention.

Key Market Indicators

Sources: Australian Centre for Disease Control, China CDC, and WHO regional surveillance updates.

Market Drivers

Earlier treatment decisions from near-patient testing. Antiviral treatment is time-sensitive, which increases the value of tests that provide clinically useful results during the same visit. CDC guidance recommends starting treatment as soon as possible, ideally within two days of symptom onset, for higher-risk patients. Roche's cobas liat respiratory assays provide molecular results in about 20 minutes, while QuidelOrtho's QUICKVUE Influenza + SARS Test provides influenza A, influenza B, and SARS-CoV-2 antigen results in as fast as 10 minutes. These products target settings where diagnostic delay can alter treatment decisions.

Expansion of multiplex respiratory testing. Influenza symptoms overlap with several viral and bacterial respiratory infections, reducing the value of tests that identify only one pathogen in some clinical settings. Multiplex panels address this problem by testing several targets from one specimen. bioMérieux's BIOFIRE Respiratory 2.1 panel identifies up to 22 respiratory pathogen targets, including influenza A, influenza B, RSV, and several other viruses and bacteria. Seegene similarly offers respiratory panels based on real-time PCR. Such platforms support laboratories and hospitals that need broader diagnostic information without running multiple separate assays.

Stronger influenza surveillance capacity. National influenza laboratories and public health systems need continuous virus detection to monitor circulating strains and support seasonal preparedness. WHO's GISRS provides weekly virological data through FluNet, while South-East Asian countries have expanded laboratory networks and quality-assurance activities for influenza testing. China's National Influenza Center also maintains regular weekly surveillance reports. These systems create recurring requirements for molecular testing, reference laboratory equipment, reagents, and related diagnostic supplies, particularly during seasonal peaks and unusual outbreaks.

Closer attention to vulnerable age groups. Children and older adults generate disproportionate clinical attention because influenza can lead to more severe complications in these groups. Treatment guidance specifically identifies young children and adults aged 65 years and older among groups requiring prompt antiviral consideration. Diagnostic suppliers therefore have an opportunity to address hospitals, pediatric facilities, urgent-care settings, and laboratories where rapid differentiation of influenza from other respiratory infections affects patient management. Roche's respiratory testing portfolio explicitly targets higher-risk populations, while CDC guidance supports early treatment for patients at elevated risk.

Market Restraints and Challenges

Sensitivity and performance differences between rapid antigen and molecular tests. Rapid antigen testing offers low equipment requirements and fast results, but its lower analytical sensitivity can limit its usefulness when viral loads are low. Australia's Therapeutic Goods Administration states that influenza rapid antigen self-tests are less sensitive than nucleic acid amplification tests and identifies NAAT as the preferred rapid diagnostic method for clinical diagnosis. This creates a trade-off for buyers between lower-cost, simpler testing and higher-performance molecular systems. Suppliers must therefore position products according to the clinical setting rather than compete on turnaround time alone.

Different regulatory requirements across Asian markets. Diagnostic manufacturers must manage separate approval, registration, reimbursement, and procurement processes across countries. Product availability can also differ by market, as demonstrated by bioMérieux's respiratory panels, whose availability varies by country. The need for local registration and evidence packages can extend launch schedules and increase compliance costs. Smaller suppliers face a greater burden because they may lack local regulatory teams, distribution partners, and post-market support infrastructure. Regional expansion therefore depends on regulatory execution as much as assay performance.

Seasonal demand creates utilization volatility. Influenza testing does not generate uniform demand throughout the year. Australia reported elevated interseasonal activity in early 2025, a prolonged June to August peak, and a slower decline than in prior seasons. China and South-East Asian surveillance likewise show changing activity by season and geography. Laboratories must maintain enough capacity for peaks without carrying excessive unused equipment or inventory during quieter periods. This creates pressure on purchasing decisions, reagent forecasting, staffing, and distributor inventory management.

Virus evolution requires continual assay and treatment monitoring. Influenza viruses change over time, affecting surveillance, vaccine composition, and diagnostic performance requirements. WHO updates seasonal vaccine recommendations twice each year based on global surveillance, while national laboratories monitor genetic and antigenic characteristics. China reported reduced susceptibility to neuraminidase inhibitors in a subset of A(H1N1)pdm09 samples in late 2025, although the other reported influenza groups remained susceptible in that analysis. Suppliers and healthcare systems therefore need ongoing surveillance rather than static product planning.

Major Segment Analysis

Molecular Tests / NAATs

Molecular Tests / NAATs represent a commercially important diagnostic category because they combine higher analytical performance with the ability to differentiate influenza from other respiratory pathogens. Their value is strongest in hospitals, reference laboratories, emergency settings, and point-of-care sites where treatment decisions depend on reliable results. WHO documentation identifies molecular influenza testing as more reliable than rapid antigen testing, although it carries higher cost.

The segment is also moving beyond single-pathogen assays. Roche's cobas liat platform can detect influenza A, influenza B, and RSV in about 20 minutes, while multiplex systems from bioMérieux and QIAGEN extend testing across broader respiratory pathogen menus. Buyers therefore assess not only sensitivity, but also turnaround time, throughput, instrument footprint, automation, consumable cost, connectivity, and menu breadth. These factors favor suppliers able to integrate molecular testing into existing laboratory or near-patient workflows.

Regional Analysis

WHO surveillance data illustrates the wide variation in testing activity across these markets. Between epidemiological week 1 and week 32 of 2025, China reported 914,932 specimens processed through the Western Pacific surveillance system, compared with 147,074 in Australia, 11,869 in Japan, 10,741 in South Korea, 3,428 in Indonesia, and 4,828 in Singapore. The same dataset recorded 84,692 influenza-positive specimens in China, 9,836 in Australia, 2,249 in Japan, 2,048 in South Korea, 808 in Indonesia, and 913 in Singapore. These figures reflect surveillance reporting rather than total national testing, but they show the substantial differences in laboratory activity across the selected markets.

China represents the largest laboratory testing environment among the countries with comparable WHO Western Pacific surveillance data. The country's national influenza surveillance system supports sustained specimen collection and virus characterization, while changes in circulating strains require laboratories to maintain flexible diagnostic capability. China CDC's surveillance reports also show that the predominant influenza type can change during the year, increasing the value of assays capable of distinguishing influenza A and B and supporting broader respiratory testing.

Japan and South Korea have mature surveillance structures and established hospital-based diagnostic practices. WHO recorded 2,249 influenza-positive specimens from Japan and 2,048 from the Republic of Korea through week 32 of 2025. The relatively developed laboratory infrastructure in both markets creates scope for molecular testing, multiplex respiratory panels, and rapid systems that reduce turnaround time without adding substantial workflow complexity.

India, Thailand, and Indonesia present a different commercial environment. Demand is influenced by large patient populations, seasonal respiratory illness, public-health surveillance, and differences in access between urban tertiary facilities and lower-tier healthcare settings. Indonesia's WHO-supported surveillance network includes both influenza-like illness and severe acute respiratory infection monitoring, while India's market has greater potential for lower-cost rapid diagnostics alongside molecular systems in larger hospitals and laboratories. WHO maintains integrated influenza surveillance updates for its South-East Asia member states, reflecting the continuing role of laboratory networks in regional monitoring.

Taiwan, Australia, and Singapore combine established healthcare systems with active influenza surveillance. Australia processed 147,074 specimens and reported 9,836 positive specimens through week 32 of 2025, while Singapore processed 4,828 specimens and reported 913 positives. Taiwan's mature healthcare and laboratory environment supports demand for higher-performance testing, whereas Singapore's smaller market favors suppliers that can combine rapid turnaround, multiplex capability, and efficient laboratory workflows.

Overall, the APAC opportunity differs materially by country. China offers scale and extensive laboratory activity, Japan and South Korea favor established clinical and laboratory workflows, India and Indonesia offer volume alongside infrastructure and affordability constraints, and Australia, Taiwan, Singapore, and Thailand provide markets where surveillance quality and testing efficiency carry greater weight in purchasing decisions. This country-level variation makes local registration, distribution, service support, pricing, and assay positioning important determinants of commercial performance through 2031.

Competitive Landscape

Competition spans large diversified diagnostic companies, specialist molecular-testing suppliers, and regional manufacturers. Abbott competes through rapid and molecular point-of-care testing, while Roche combines laboratory and near-patient molecular platforms. bioMérieux and QIAGEN emphasize syndromic testing, with BIOFIRE and QIAstat-Dx addressing broader respiratory pathogen detection. Seegene contributes multiplex PCR capability, while QuidelOrtho maintains a strong rapid-testing position through its influenza portfolio.

The remaining companies in the supplied competitive set, including Thermo Fisher Scientific, Becton, Dickinson and Company, Siemens Healthineers, and SD Biosensor, broaden competition across molecular diagnostics, laboratory systems, antigen testing, and respiratory assays. Competitive differentiation increasingly depends on assay breadth, turnaround time, instrument compatibility, installed workflow, regulatory approvals, distribution reach, and consumable economics. Suppliers with broad respiratory menus can also reduce dependence on influenza-only testing by serving multiple seasonal pathogens through one platform.

Recent Developments

• September 2025: QuidelOrtho announced availability of its QUICKVUE Influenza + SARS Test for professional use. The rapid immunoassay differentiates influenza A, influenza B, and SARS-CoV-2 from one sample in as fast as 10 minutes, targeting decentralized clinical settings.

• September 2025: QIAGEN received U.S. clearance for QIAstat-Dx Rise, expanding its automated syndromic testing platform with Respiratory Panel Plus and Respiratory Panel Mini. The system can process up to 160 samples per day, strengthening its position in higher-throughput respiratory testing.

• August 2025: Roche received FDA 510(k) clearance for cobas Respiratory 4-flex, a multiplex PCR assay detecting SARS-CoV-2, influenza A, influenza B, and RSV. The product adds a customizable respiratory testing option to Roche's laboratory portfolio.

• April 2025: bioMérieux launched WATCHFIRE, a molecular wastewater surveillance solution with a respiratory panel targeting 22 pathogens, including influenza A and B. The launch extends influenza detection beyond clinical testing into population-level respiratory surveillance.

Regulatory and Policy Environment

WHO surveillance and vaccine-composition decisions remain central to the regional operating environment. WHO issues influenza vaccine composition recommendations twice each year, using data from GISRS and collaborating laboratories. For the 2026 southern hemisphere season, the recommended trivalent composition included H1N1pdm09, H3N2, and B/Victoria components. For the 2026-2027 northern hemisphere season, WHO issued a different composition reflecting continued viral evolution. These changes affect manufacturers, national regulators, procurement planning, and surveillance laboratories.

Diagnostic regulation also influences product design and market entry. Australia, for example, requires influenza self-tests to meet defined clinical sensitivity and specificity thresholds and recognizes the lower sensitivity of rapid antigen testing compared with NAAT. In Asia, manufacturers must satisfy national registration and performance requirements, while public laboratories must maintain quality systems and surveillance standards aligned with national and WHO programs.

Antiviral policy adds another layer to treatment demand. CDC guidance identifies neuraminidase inhibitors such as oseltamivir, zanamivir, and peramivir, alongside the cap-dependent endonuclease inhibitor baloxavir, as treatment options under specified clinical conditions. Regional treatment protocols may differ, but early treatment, resistance monitoring, age-specific use, and availability remain important factors in therapeutic planning.

Outlook and Strategic Implications

The 2026-2031 market should develop around a wider diagnostic role for influenza testing rather than influenza-only detection. Hospitals and laboratories increasingly need to distinguish influenza from SARS-CoV-2, RSV, and other respiratory infections using limited samples and short turnaround times. This favors molecular and multiplex platforms where testing volumes justify equipment and reagent costs, while rapid antigen products retain a role in lower-complexity and decentralized settings.

Regional suppliers will need to balance performance with affordability, local registration, service coverage, and supply reliability. The opportunity is not uniform across APAC. Japan, South Korea, Australia, Singapore, Taiwan, and China offer comparatively developed testing ecosystems, while India, Indonesia, Thailand, and other emerging markets offer opportunities tied to laboratory expansion, surveillance strengthening, and broader access to rapid diagnostics.

For manufacturers, the strongest commercial positions will depend on flexible respiratory menus, efficient workflows, and country-specific regulatory execution. For hospitals and laboratories, platform economics will increasingly depend on the ability to use installed systems across several respiratory diseases rather than influenza alone. Public health agencies will continue to require reliable surveillance, strain characterization, and resistance monitoring, while antiviral suppliers will need to align treatment availability with seasonal activity and evolving clinical guidance. WHO's continuing surveillance and twice-yearly vaccine composition process will remain an important external input into product planning through the forecast period.

Asia Pacific (APAC) Flu Diagnostic and Treatment Market Scope: